ASH Conference Coverage

HIV Drug Active in Refractory Myeloma

(MedPage Today) Dec 8, 2016 - Two-thirds of patients with proteasome inhibitor-refractory myeloma responded to the antiretroviral agent nelfinavir, added to standard myeloma agents, according to a small study reported here.

read article (free registration required)

Phase III Studies Present Additional Evidence for REVLIMID® (lenalidomide) as Maintenance Therapy in Multiple Myeloma

(Celgene) Dec 6, 2016 - Celgene Corporation, today announced results from two studies (Abstracts #1143, LBA-1) evaluating the investigational use of REVLIMID® (lenalidomide) maintenance therapy in patients with multiple myeloma.

read corporate press release

First Multicenter Trial Finds CAR T-Cell Immunotherapy Effective, Feasible for Hard-to-Treat Lymphoma

(ASH) Dec 6, 2016 - A late-breaking abstract being presented today during the 58th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego demonstrates that chimeric antigen receptor (CAR) T-cell therapy is a promising option for treating refractory non-Hodgkin lymphoma and practical to implement in a variety of real-world clinical settings.

read press release

Additions to Standard Multiple Myeloma Therapy Do Not Appear to Yield Additional Benefit

(ASH) Dec 6, 2016 - Largest randomized trial finds second round of chemotherapy or stem cell transplant does not improve progression-free survival.

read press release

New Data Shed Light on Potential Advantages of Pacritinib for Patients with Myelofibrosis

(ASH) Dec 6, 2016 - Pacritinib, currently on hold by the FDA, appears to be more effective in reducing spleen volume; twice-daily dose improves symptoms. This analysis comes from data before the clinical hold.

read press release

IKZF1 Gene Mutations Found to Increase Hereditary Risk for Acute Lymphocytic Leukemia in Children

(ASH) Dec 6, 2016 - A late-breaking abstract being presented today during the 58th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego identifies inherited genetic mutations in the gene IKZF1 that confer a higher likelihood of developing pediatric acute lymphocytic leukemia (ALL).

read press release

Juno Therapeutics Highlights Progress with Best-in-Class Strategy in B-Cell Malignancies at ASH

(Juno Therapeutics) Dec 6, 2016 - Juno Therapeutics, Inc., a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today provided an update of key data from studies of its investigational chimeric antigen receptor (CAR) T cell product candidates, presented at the 58th American Society of Hematology Annual Meeting in San Diego, December 3-6, 2016.

read corporate press release

How is European Immuno-Oncology Fighting Blood Cancer?

(labiotech.eu) Dec 6, 2016 - From leukemia to multiple myeloma, biotech is working hard to cure blood cancer. This year’s edition of the American Society of Hematology (ASH) annual meeting features immuno-oncology therapies developed by the best European biotechs, with Novartis taking the lead in the CAR-T field.

read article

Standing Up To The Test Of Time: Two Cancer Drugs That Could Survive A Hobbled FDA

(Forbes) Dec 7, 2016 - If the Food and Drug Administration gets gutted, and pressured by politicians to lower its standards to allow more drugs on the market more quickly, how would that change the pharmaceutical business?

read article

Psychosocial Factors Associated With High Readmission Rates Longer Hospital Stays

(OSUCCC - The James) Dec 5, 2016 - A new study shows that psychosocial risk factors that impact a person’s ability to cope with chronic stress are associated with significantly higher readmission rates and longer hospital stays among blood cancer patients undergoing hematopoietic stem cell transplantation (HSCT).

read press release

MorphoSys Presents Updated Clinical Data for Blood Cancer Candidate MOR208 in NHL and CLL at ASH 2016 Conference

(Yahoo! Finance) Dec 6, 2016 - MorphoSys AG announced today the presentation of updated safety and efficacy data from two ongoing phase 2 clinical studies evaluating MOR208, an Fc-modified investigational antibody targeting CD19, in patients with advanced B-cell malignancies, at the 58th American Society of Hematology (ASH) Annual Meeting in San Diego, California/USA.

read article

Seattle Genetics and Bristol-Myers Squibb Highlight First Data from Phase 1/2 Study Evaluating ADCETRIS (Brentuximab Vedotin) in Combination with Opdivo (nivolumab) in Relapsed or Refractory Hodgkin Lymphoma at ASH Annual Meeting

(Biotech-365) Dec 6, 2016 - Seattle Genetics, Inc. and Bristol-Myers Squibb Company today highlighted the first reported data from an ongoing phase 1/2 clinical trial evaluating ADCETRIS (brentuximab vedotin) in combination with Opdivo (nivolumab) in relapsed or refractory classical Hodgkin lymphoma (HL) at the 58th American Society of Hematology (ASH) Annual Meeting and Exposition taking place in San Diego, California, December 3-6, 2016.

read article

New Ibrutinib (IMBRUVICA) Phase 2 Data Demonstrate Promise in Relapsed/Refractory Marginal Zone Lymphoma (MZL), a Rare, Incurable Type of Non-Hodgkin's Lymphoma

(TheStreet) Dec 5, 2016 - Half of patients with relapsed/refractory MZL responded to ibrutinib, as presented at the American Society of Hematology Annual Meeting.

read article

Late-Breaking Ibrutinib (IMBRUVICA) Data Show Complete or Partial Response in Two-Thirds of Patients with Chronic Graft-Versus-Host-Disease, a Frequent and Potentially Life-Threatening Complication of Stem Cell Transplant

(Yahoo! Finance) Dec 6, 2016 - AbbVie, a global biopharmaceutical company, today announced positive results from a Phase 2 study (PCYC-1129) evaluating ibrutinib (IMBRUVICA®) in patients with chronic graft-versus-host-disease (cGVHD), a serious and debilitating potential consequence of stem cell or bone marrow transplant,1 who failed prior systemic therapy.

read article

Daratumumab (DARZALEX®) Combination Therapy Showed Consistent Clinical Benefit for Previously-Treated Patients with Multiple Myeloma

(The Business Journals) Dec 5, 2016 - Post-hoc analyses of the Phase 3 POLLUX and CASTOR studies to be presented at the 58th American Society of Hematology (ASH) Annual Meeting.

read article

ARIAD Announces Data Presentations at American Society of Hematology Meeting

(Digital Journal) Dec 6, 2016 - ARIAD Pharmaceuticals, Inc. today announced the results of clinical and translational studies on Iclusig® (ponatinib), its approved BCR-ABL inhibitor, in heavily pretreated patients with resistant or intolerant chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).

read article

Combined Analysis of Oral Epigenetic Therapy, CC-486, Demonstrated Hematologic Responses in Patients Who Received Prior Epigenetic Hypo-Methylating Agents (HMA)

(MarketWatch) Dec 5, 2016 - Patients with MDS, CMML or AML who were relapsed or refractory to prior HMA therapies and who received CC-486 had a 38% overall response rate.

read article

Karyopharm Presents Updated Phase 1b STOMP Data at the American Society of Hematology 2016 Annual Meeting

(NASDAQ) Dec 5, 2016 - STOMP data continues to demonstrate high response rates in patients with heavily pretreated multiple myeloma when selinexor is combined with bortezomib and pomalidomide.

read article

New Analysis Shows People with Cancer Who Received XARELTO® (rivaroxaban) for Blood Clots Had Fewer ER Visits and Lower Healthcare Costs than Those Given Standard Treatment

(Yahoo! Finance) Dec 6, 2016 - A new analysis shows people with cancer treated with XARELTO® (rivaroxaban) for blood clots had significantly fewer emergency room (ER) visits and lower healthcare costs at initiation of therapy than those given standard treatment.

read article

New Interim Data Demonstrate Sandoz Proposed Biosimilar Rituximab Has Equivalent Efficacy To Reference Product

(Sandoz) Dec 5, 2016 - ASSIST-FL trial demonstrates equivalent safety, efficacy, pharmacokinetics and pharmacodynamics of Sandoz proposed biosimilar rituximab (GP2013) to the reference product; interim data in over 600 adults show potential of GP2013 as an alternative rituximab.

read corporate press release
Next Page